SPY001 Phase 2 SKYLINE Trial Achieves Primary Endpoint with Positive Ulcerative Colitis Data, Advancing Combination Cohorts
SYRE has more than doubled off its 52-week low of $10.91.
Summary
Spyre Therapeutics reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001 in ulcerative colitis, meeting the primary endpoint and showing strong secondary efficacy with a favorable safety profile.
Key Events · Product Development and Regulatory · SYRE
-
SPY001 Phase 2 Data Positive
Spyre Therapeutics announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for moderate-to-severely active ulcerative colitis.
-
Primary Endpoint Met
SPY001 achieved the primary endpoint, demonstrating a statistically significant reduction in the Robarts Histopathology Index (RHI) score of 9.2 points (p<0.0001).
-
Strong Secondary Efficacy
Key secondary endpoints showed clinically meaningful rates of clinical remission (40%) and endoscopic improvement (51%).
-
Favorable Safety Profile
SPY001 was well tolerated with a safety profile consistent with the α4β7 class; one serious adverse event was deemed not drug-related.
Analysis · SYRE · Life Sciences
Spyre Therapeutics announced highly positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001 in moderate-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant reduction in the Robarts Histopathology Index (RHI) score and demonstrated clinically meaningful rates for key secondary endpoints like clinical remission and endoscopic improvement. The favorable safety profile, consistent with its class, further de-risks the asset. This strong clinical validation for SPY001, especially as the company progresses to Part B of the trial to evaluate combination therapies, is a significant catalyst for a life sciences company, reinforcing its pipeline and potential market position. This news provides strong fundamental support for the stock, which is currently trading near its 52-week high.
At the time of this filing, SYRE was trading at $63.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $10.91 to $54.39. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.